To know antipneumococcal vaccination coverages among Catalonian adults and evaluate the
adequacy of vaccine use according to 3 distinct current vaccination
guidelines.
Population-based cross-sectional study.
Primary Health Care. Catalonia, Spain.
A total of 2,033,465 individuals≥50 years-old registered in the Catalonian Health Institute.
Vaccination status for the 23-valent pneumococcal polysaccharide vaccine (PPV23) and/or the 13-valent pneumococcal conjugate vaccine (PCV13) was revised at 1/01/2015.
Adequacy of vaccination status was determined according to 3 distinct vaccination recommendation
guidelines: Spanish Ministry of Health (basically coinciding with Catalonian Health Institute\'s recommendations), Spanish Society of Family Physicians (semFYC) and Centers for Disease Control and Prevention (CDC).
Overall, 789,098 (38.8%) persons had received PPV23 and 5,031 (0.2%) had received PCV13. PPV23 coverage largely increased with increasing age (4.8% in 50-59 years, 35.5% in 60-69 years, 71.9% in 70-79 years and 79.5% in≥80 years; P<.001), whereas PCV13 coverage was very small in all age groups. Considering the 3 analysed vaccine
guidelines a 46.1% of the overall study population were
adequacy vaccinated according to Spanish Ministry\'s recommendations, 19.3% according to semFYC\'s recommendations and 4.6% according to CDC\'s recommendations.
PPV23 coverage among Catalonian adults may be considered as intermediate, but PCV13 coverage is very small. The institutional recommendations (Spanish Ministry) are more followed than corporative (semFYC) or less local (CDC) recommendations in clinical practice.